Welcome to our dedicated page for MYOV news (Ticker: MYOV), a resource for investors and traders seeking the latest updates and insights on MYOV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MYOV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MYOV's position in the market.
Myovant Sciences (NYSE: MYOV) will hold a webcast and conference call to discuss its corporate updates and financial results for Q2 fiscal 2022, ending September 30, 2022. The event is set for October 26, 2022, at 5:00 PM ET. Investors can access the live webcast via Myovant's investor relations page. The company aims to redefine care in women's and men's health with successful Phase 3 trials leading to FDA approvals across multiple conditions. They also have ongoing studies and a supplemental New Drug Application under review, reflecting their commitment to innovation in healthcare.
Myovant Sciences Ltd. (NYSE: MYOV) received a non-binding acquisition proposal from Sumitovant Biopharma Ltd. and Sumitomo Pharma Co. Ltd. to purchase the remaining shares at $22.75 each. Sumitovant holds approximately 52% of Myovant's shares. The board's Special Committee has deemed the offer significantly undervalued and not in the best interest of shareholders but remains open to better proposals. The Committee has engaged financial and legal advisors for the evaluation. No agreement has been finalized, and shareholders need not take actions at this time.
Myovant Sciences (NYSE: MYOV) announced the approval of equity awards for 7 new employees, granting them a total of 37,700 restricted stock units (RSUs) as part of its 2020 Inducement Plan. The RSUs will vest over a period of time, with one-fourth vesting after one year and the remainder in twelve quarterly installments. Myovant aims to innovate care for men and women through science and advocacy, having previously achieved regulatory approvals for treatments in oncology and women's health. The company is also reviewing a supplemental New Drug Application with the FDA.
Myovant Sciences (NYSE: MYOV) has launched a new educational campaign to encourage prostate cancer patients to engage in conversations about their condition. This initiative coincides with Prostate Cancer Awareness Month and aims to address the communication barriers faced by patients. The new video series, “Men With Prostate Cancer Find Support”, showcases personal experiences and available resources. Myovant also sponsors educational events to further support affected individuals.
Urovant Sciences announced that its investigational gene therapy, URO-902, received the Best in Category Prize: Overactive Bladder from the
Myovant Sciences (NYSE: MYOV) announced participation in two investor conferences: Citi's 17th Annual BioPharma Conference on September 8, 2022, with one-on-one meetings, and Baird's 2022 Global Healthcare Conference on September 13, 2022, featuring a fireside chat and additional investor meetings. The public can access the Baird fireside chat via the company's Events page. Myovant aims to redefine care for men and women, boasting five successful Phase 3 clinical trials leading to three FDA approvals and ongoing studies for further drug applications, including MYFEMBREE.
Myovant Sciences (NYSE: MYOV) announced the approval of equity awards for 11 new employees under its 2020 Inducement Plan on August 15, 2022. The total grant comprises 120,550 restricted stock units (RSUs), with a vesting schedule of one-fourth after one year and the remainder in quarterly installments, contingent on employment status. Myovant aims to advance care for men and women through innovative science, having completed five Phase 3 clinical trials leading to multiple FDA approvals. The company is actively developing treatments in women's health and oncology.
Myovant Sciences reported total revenue of $116.5 million for Q1 2022, significantly up from $41.1 million in Q1 2021. Notably, net product revenue from ORGOVYX® reached $36.0 million with a 26% sequential growth, while MYFEMBREE® generated $4.0 million, marking a 54% growth. MYFEMBREE is now the market leader in GnRH antagonist therapies with a 51% total prescription share. The FDA is expected to decide on MYFEMBREE's supplemental NDA by August 6, 2022. Myovant ended the quarter with $400 million in cash and equivalents.
Myovant Sciences (NYSE: MYOV) announced equity awards for nine new employees as part of its 2020 Inducement Plan, granting a total of 175,600 restricted stock units (RSUs) on July 15, 2022. The RSUs will vest over four years, contingent on continued employment. Myovant has achieved significant milestones, including multiple Phase 3 clinical trial successes and FDA approvals for treatments related to prostate cancer and uterine fibroids. The company continues to seek FDA approvals for additional indications and is conducting further clinical studies.
